Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Apellis Pharmaceuticals ( (APLS) ) has issued an update.
On February 27, 2026, Apellis Pharmaceuticals’ board elected Mikael Dolsten, M.D., Ph.D., as an independent Class I director, effective March 1, 2026, with a term running until the 2027 annual meeting of stockholders, reflecting a continuation of standard U.S. public company governance practices. Dolsten, who has no family or related-party ties to existing management or directors and no underlying arrangements for his election, will receive stock options and RSUs valued at $300,000 each under Apellis’ 2017 Stock Incentive Plan, with multi-year and change-in-control vesting features that align his incentives with long-term shareholder interests while also benefiting from an indemnification agreement customary for the company’s board members.
The most recent analyst rating on (APLS) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Apellis Pharmaceuticals stock, see the APLS Stock Forecast page.
Spark’s Take on APLS Stock
According to Spark, TipRanks’ AI Analyst, APLS is a Neutral.
The score is driven primarily by improving financial performance (profitability and cash flow turning positive and a delevered balance sheet) and a constructive earnings call (EMPAVELI launch momentum and supportive SYFOVRE demand/data), partially offset by weak technical trend signals and a high P/E that leaves less margin for execution errors amid ongoing net revenue headwinds (free goods/gross-to-net) and near-term variability.
To see Spark’s full report on APLS stock, click here.
More about Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies, including complement inhibitors, for serious diseases with high unmet medical need. The company operates in the U.S. and global markets, with its governance structure aligned to Nasdaq listing standards and typical public-company practices.
Average Trading Volume: 2,843,814
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.68B
Find detailed analytics on APLS stock on TipRanks’ Stock Analysis page.